» Articles » PMID: 15064006

The Lymph Node Ratio As Prognostic Factor in Node-positive Breast Cancer

Overview
Journal Radiother Oncol
Specialties Oncology
Radiology
Date 2004 Apr 6
PMID 15064006
Citations 52
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Purpose: The clinical records of the node-positive breast cancer patients treated at our department were reviewed, to evaluate if there is a correlation between the ratio of involved axillary lymph nodes and the overall and cause specific survival.

Patients And Methods: From 1984 until July 2001, 2073 files from patients with an invasive breast carcinoma were submitted to retrospective analyses. In 810 cases, a node positive status was diagnosed. All pT-stages were included. The total number of dissected nodes (pNtot) and the number of involved nodes (pN+) were available for 741 patients. The ratio of nodal involvement (pN+%) was categorized into three groups, pN+%< or =10% (n = 212) between 11 and 50% (n = 346) and between 51 and 100% (n = 183).

Results: The actuarial overall survival (OS) at 5 and 10 years was, respectively, 78.2 and 59.1%. Cause specific survival (CSS) rates were, respectively, 83.6 and 69.1%. In univariate analyses, age (P = 0.01), grade (P = 0.02), pT-stage (P < 0.0001), chemotherapy (P = 0.0002), the number of involved nodes < or =3 versus >3 (pN+) (P < 0.0001) and ratio pN+% (P < 0.0001) were associated significantly with overall survival. A multivariate analysis using the Cox proportional hazards model found that pN+% was the most significant prognostic factor; pN+lost significance when pN+% was taken into account.

Conclusions: The percentage of positive lymph nodes in an axillary lymph node dissection appears to be an important prognostic factor for survival. The nodes ratio improved on the absolute numbers of involved axillary lymph nodes for assessment of prognosis.

Citing Articles

Predictive value of number of metastatic lymph nodes and lymph node ratio for prognosis of patients with FIGO 2018 stage IIICp cervical cancer: a multi-center retrospective study.

Ye Y, Lian R, Li Z, Chen X, Huang Y, Yao J BMC Cancer. 2024; 24(1):1005.

PMID: 39138415 PMC: 11320992. DOI: 10.1186/s12885-024-12784-8.


Evaluating the role of MEN1 gene expression and its clinical significance in breast cancer patients.

Massey S, Khan M, Rab S, Mustafa S, Khan A, Malik Z PLoS One. 2023; 18(7):e0288482.

PMID: 37437063 PMC: 10337982. DOI: 10.1371/journal.pone.0288482.


The role of radiotherapy in the management of nodal disease in breast cancer.

Lenihan J, Rangaswamy G, Faul C Rep Pract Oncol Radiother. 2022; 27(2):331-343.

PMID: 36299373 PMC: 9591026. DOI: 10.5603/RPOR.a2022.0037.


The prognostic value of the number of positive lymph nodes and the lymph node ratio in early-stage cervical cancer.

Olthof E, Mom C, Snijders M, Wenzel H, van der Velden J, van der Aa M Acta Obstet Gynecol Scand. 2022; 101(5):550-557.

PMID: 35218205 PMC: 9564443. DOI: 10.1111/aogs.14316.


Predictive Value of Pretreatment Peripheral Neutrophil-to-Lymphocyte Ratio for Response to Neoadjuvant Chemotherapy and Breast Cancer Prognosis.

Li X, Tan Q, Li H, Yang X Cancer Manag Res. 2021; 13:5889-5898.

PMID: 34349562 PMC: 8326279. DOI: 10.2147/CMAR.S313123.